Vascular Biogenics Ltd (VBLT)

[mantoo123]

From listening to Dr. Harats, it seems that VB-111 shows therapeutic results after a delay of a few months. Some patients die before they have a chance to react. As I understand it, the Ovarian P2 trials initial results (after the first 3-6 months) were quite disappointing. Nevertheless, I think the people at the FDA are far from stupid and will be able to identify the therapeutic benefits of VB-111 if there is any.

The fact that the Or Yehuda facility is being built for $20 million dollars shows the conviction VBL management has in their product. It's a calculated risk which will pay off very nicely if and when VB-111 is approved.

In addition, the people managing VBL give the impression of being very experienced and know how to navigate around difficulties of their field.

On another register, I understand that the adenovirus contained in VB-111 induces cell death in angiogenic endothelial cells in the tumor milieu. However, does this adenovirus infect ALL cells in the body or only angiogenic endothelial cells?